Holocene Advisors’s Kezar Life Sciences KZR Stock Holding History

Holocene Advisors’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-74,850	Closed	-$6.19M	–	886
2022 Q2	$6.19M	Buy	+74,850	New	+$6.6M	0.04%	300

Other funds holding KZR

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Holocene Advisors's KZR Position: Q2 2022 in Review

Holocene Advisors sold out of Kezar Life Sciences (KZR) in Q2 2022, closing a stake of 157,305 shares — an estimated $13.9M sold.

Holocene Advisors first reported a position in KZR in Q4 2021 and held it in 2 quarters. The position peaked at $26.1M in Q1 2022. 127 funds tracked by Wall St. Rank hold KZR as of Q2 2022.

Holocene Advisors reported no remaining Kezar Life Sciences position as of Q2 2022 after selling out during the quarter.
Holocene Advisors sold 157,305 Kezar Life Sciences shares in Q2 2022, an estimated $13.9M.
Holocene Advisors first reported a position in Kezar Life Sciences in Q4 2021 and held it in 2 quarters.
Holocene Advisors's Kezar Life Sciences position peaked at $26.1M in Q1 2022.
127 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2022.

Based on Holocene Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.